Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig versus placebo in late-line metastatic castration-resistant prostate cancer
NL-OMON58871Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pasritamig + best supportive care with Placebo + best supportive care (2 arms). Primary endpoint: Overall survival. Started Nov 2025; status: recruiting.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON58871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58871.